Late Breaking Abstract - International, prospective real-world study of mepolizumab in patients with severe asthma at one year: REALITI-A Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021
Late Breaking Abstract - Characterizing responders to benralizumab for severe asthma: pooled analysis of the SIROCCO and CALIMA studies Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017
Late Breaking Abstract - LUSTER-1 and -2: randomised controlled trials of fevipiprant in severe asthma Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020
Late Breaking Abstract - Masitinib in severe asthma: Results from a randomized, phase 3 trial Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020
Late Breaking Abstract - Tocilizumab administration for the treatment of hospitalised patients with COVID-19: A systematic review and meta-analysis Source: Virtual Congress 2021 – Challenges of COVID-19 management at short and long-term Year: 2021
Late Breaking Abstract - Predictive value of FeNO in patients with non-specific respiratory symptoms: a randomised controlled trial Source: International Congress 2017 – Primary care management of respiratory symptoms, allergies, inhalers and adherence Year: 2017
Late Breaking Abstract - Tocilizumab in hospitalized patients with severe COVID-19: an open label, prospective study Source: Virtual Congress 2021 – Respiratory infections Year: 2021
Late Breaking Abstract - Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017
Late Breaking Abstract - Compare outcomes between COPD patients treated with Tiotropium/Olodaterol (TIO/OLO) and other fixed-dose LAMA/LABAs Source: Virtual Congress 2020 – COPD and the impact of comorbidities Year: 2020
Late Breaking Abstract - ENose based phenotyping of newly presented patients with asthma or COPD Source: International Congress 2018 – Biomarkers in COPD and asthma Year: 2018
Late Breaking Abstract - Impact of ICS/LABA and LABA/LAMA FDCs on lung function and exacerbation of COPD: a network meta-analysis Source: International Congress 2018 – Pharmacological management of COPD Year: 2018
Late Breaking Abstract - The humanistic burden of asthma patients uncontrolled on ICS-LABA: a systematic literature review Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020
Late Breaking Abstract - Telerehabilitation compared to centre-based pulmonary rehabilitation: a randomised controlled equivalence trial. Source: Virtual Congress 2020 – ALERT: Ventilation and rehabilitation Year: 2020
Late Breaking Abstract - Can a self-management plan, which includes a four-fold increase in inhaled corticosteroid dose, reduce severe asthma exacerbations: a randomised, pragmatic trial. Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017
Late Breaking Abstract - Analysis of the InforMing the PAthway of COPD Treatment (IMPACT) study in the subgroup of patients taking triple therapy at screening Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018
Late Breaking Abstract - Identification of patients with COPD who benefit from benralizumab Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: COPD and cough Year: 2019
Late Breaking Abstract - Extrafine triple therapy reduces exacerbations in GOLD B COPD patients: post-hoc analysis of TRILOGY and TRINITY Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017
Late Breaking Abstract - Long-term safety and efficacy of benralizumab in severe, uncontrolled asthma: first results of BORA, a randomized, Phase III extension study Source: International Congress 2018 – Notable Studies in Asthma Year: 2018
Late Breaking Abstract - Effects of a new airway clearance technology in children with cystic fibrosis - A homecare randomized controlled trial Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects Year: 2021
Roflumilast for stable COPD: Meta-analysis of randomized controlled trials Source: International Congress 2014 – Clinical presentations Year: 2014